Next-Generation Substernal Pacing Lead for Personalized Cardiac Therapy

A novel implantable cardioverter-defibrillator system featuring a substernal pacing lead with integrated sensors for real-time cardiac arrhythmia monitoring and an ICD with artificial intelligence for personalized therapy adaptation, enabling more effective and efficient cardiac care.

The original patent's implantable cardioverter-defibrillator system, while effective, has limitations in providing personalized cardiac therapy. The new inventive concept addresses this limitation by integrating real-time cardiac activity monitoring and artificial intelligence-driven therapy adaptation, enabling more effective and efficient cardiac care.

The next-generation substernal pacing lead features integrated sensors for real-time monitoring of cardiac arrhythmias, which transmit data to the ICD. The ICD, equipped with an artificial intelligence module, receives sensor data and adjusts therapy accordingly. The system utilizes machine learning algorithms and patient-specific data to adapt pacing and defibrillation protocols, providing personalized cardiac therapy. The ICD also features a communication interface for remote software updates and data analysis, ensuring continuous improvement and optimization.

The integration of real-time cardiac activity monitoring and artificial intelligence-driven therapy adaptation in the substernal pacing lead and ICD, respectively, constitutes a novel and non-obvious improvement over the original patent, enabling more effective and efficient cardiac care.

Alternative embodiments may include wearable devices for patient monitoring, cloud-based analytics platforms for remote data analysis, or different sensor configurations for cardiac activity monitoring. Variations may include different AI algorithms, data analysis techniques, or communication protocols.

The next-generation substernal pacing lead has significant commercial potential in the cardiac care industry, particularly in the areas of personalized medicine, artificial intelligence, and remote patient monitoring. The target market includes hospitals, clinics, and medical device manufacturers.